![]() ![]() Starting from the histopathological classification up to the molecular classification, breast cancer has been constantly redefined in order to ensure a better management of the patient. The molecular heterogeneity of the normal breast tissue has been previously documented and has outlined the different molecular profiles of epithelial and non-epithelial cells responsible for the existence of several molecular types of breast carcinomas, already characterized. However, at a microscopic and molecular level, breast cancer is not a homogeneous disease, thus being the focus of numerous ongoing studies. The emerging concept of triple negative breast cancerīreast cancers are commonly associated with a high incidence and a high mortality rate in the female population worldwide. Therefore, the question: ‘Could TNBC be subject to a standardized, unanimously accepted therapeutic strategy or is it strictly subclass-dependent?’ remains to be further investigated. Whether metastases have a similar phenotype as the primary tumor remains an enigma. If TNBCs treatment depends on the molecular profile of the tumor, the same statement may be postulated for TNBCs metastasis. Despite the fact that TNBCs do not usually metastasize through the lymphatic pathways, TNBCs may be characterized by lymphatic invasion and by an increased lymphatic microvascular density. Vasculogenic mimicry detected in TNBCs, seems to be determined by a population of CD133+ cells and may be stimulated by different pharmacological agents such sunitinib. Currently, few sparse data are available in literature concerning the origins of TNBC. TNBCs “choose” young women and its “kiss” is, unfortunately deadly in most cases. One of the most controversial women malignancies, triple negative breast cancers (TNBCs) are critically overviewed here, being focused on data useful in clinical practice or to improve the therapy and patients survival. Received: FebruAccepted: MaPublished: ApAbstract Keywords: triple negative breast cancer, progression, metastases, therapeutic targets Adriana-Andreea Jitariu 1, Anca Maria Cîmpean 1, Domenico Ribatti 2,3 and Marius Raica 1ġ Department of Microscopic Morphology/Histology, Angiogenesis Research Center, Victor Babeș University of Medicine and Pharmacy, Timișoara, RomaniaĢ Department of Basic Medical Sciences, Neurosciences and Sensory Organs, University of Bari Medical School, Bari, Italyģ National Cancer Institute “ Giovanni Paolo II”, Bari, Italy
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |